

Global Vasodilators for Heart Disease Market Growth 2026-2032

<https://marketpublishers.com/r/G5705A1A14E9EN.html>

Date: February 2026

Pages: 167

Price: US\$ 3,660.00 (Single User License)

ID: G5705A1A14E9EN

Abstracts

The global Vasodilators for Heart Disease market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

United States market for Vasodilators for Heart Disease is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Vasodilators for Heart Disease is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Vasodilators for Heart Disease is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Vasodilators for Heart Disease players cover Copperhead Chemical Company, Pfizer, Axplora, TORRENT PHARMA INC., Sanofi, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Vasodilators for Heart Disease Industry Forecast" looks at past sales and reviews total world Vasodilators for Heart Disease sales in 2025, providing a comprehensive analysis by region and market sector of projected Vasodilators for Heart Disease sales for 2026 through 2032. With Vasodilators for Heart Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Vasodilators for Heart Disease industry.

This Insight Report provides a comprehensive analysis of the global Vasodilators for

Heart Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Vasodilators for Heart Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Vasodilators for Heart Disease market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Vasodilators for Heart Disease and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Vasodilators for Heart Disease.

This report presents a comprehensive overview, market shares, and growth opportunities of Vasodilators for Heart Disease market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Nitroglycerin

Isosorbide Dinitrate

Isosorbide Mononitrate

Nicorandil

Segmentation by Application:

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Copperhead Chemical Company

Pfizer

Axplora

TORRENT PHARMA INC.

Sanofi

Aditya Chemicals

Matins Pharma

Shanxi Kangbao Biological Products Co., Ltd.

Henan Runhong Pharmaceutical Co., Ltd.

Beijing Yimin Pharmaceutical Co., Ltd.

Beijing Hengsheng Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Sancai Shiqi Pharmaceutical Co., Ltd.

Lunan Beite Pharmaceutical Co., Ltd.

Shandong Fangming Pharmaceutical Group Co., Ltd.

Chenxin Pharmaceutical Co., Ltd.

Anhui Fengyuan Pharmaceutical Co., Ltd.

Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.

Shanghai Aifa Pharmaceutical Co., Ltd.

Shandong New Era Pharmaceutical Co., Ltd.

Shanghai Hefeng Pharmaceutical Co., Ltd.

Jiangsu Shenlong Pharmaceutical Co., Ltd.

Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.

Hulunbeier Songlu Pharmaceutical Co., Ltd.

Chongqing Yaoyou Pharmaceutical Co., Ltd.

Jiangsu Jiuxu Pharmaceutical Co., Ltd.

Jiangxi Haiersi Pharmaceutical Co., Ltd.

Southwest Pharmaceutical Co., Ltd.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Vasodilators for Heart Disease market?

What factors are driving Vasodilators for Heart Disease market growth, globally and by

region?

Which technologies are poised for the fastest growth by market and region?

How do Vasodilators for Heart Disease market opportunities vary by end market size?

How does Vasodilators for Heart Disease break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Vasodilators for Heart Disease Annual Sales 2021-2032
- 2.1.2 World Current & Future Analysis for Vasodilators for Heart Disease by Geographic Region, 2021, 2025 & 2032
- 2.1.3 World Current & Future Analysis for Vasodilators for Heart Disease by Country/Region, 2021, 2025 & 2032

2.2 Vasodilators for Heart Disease Segment by Type

- 2.2.1 Nitroglycerin
- 2.2.2 Isosorbide Dinitrate
- 2.2.3 Isosorbide Mononitrate
- 2.2.4 Nicorandil
- 2.2.5 Vasodilators for Heart Disease Sales by Type
 - 2.2.5.1 Global Vasodilators for Heart Disease Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Vasodilators for Heart Disease Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Vasodilators for Heart Disease Sale Price by Type (2021-2026)

2.3 Vasodilators for Heart Disease Segment by Application

- 2.3.1 Hospital
- 2.3.2 Clinic
- 2.3.3 Other
- 2.3.4 Vasodilators for Heart Disease Sales by Application
 - 2.3.4.1 Global Vasodilators for Heart Disease Sale Market Share by Application (2021-2026)

2.3.4.2 Global Vasodilators for Heart Disease Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Vasodilators for Heart Disease Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Vasodilators for Heart Disease Breakdown Data by Company

3.1.1 Global Vasodilators for Heart Disease Annual Sales by Company (2021-2026)

3.1.2 Global Vasodilators for Heart Disease Sales Market Share by Company (2021-2026)

3.2 Global Vasodilators for Heart Disease Annual Revenue by Company (2021-2026)

3.2.1 Global Vasodilators for Heart Disease Revenue by Company (2021-2026)

3.2.2 Global Vasodilators for Heart Disease Revenue Market Share by Company (2021-2026)

3.3 Global Vasodilators for Heart Disease Sale Price by Company

3.4 Key Manufacturers Vasodilators for Heart Disease Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Vasodilators for Heart Disease Product Location Distribution

3.4.2 Players Vasodilators for Heart Disease Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR VASODILATORS FOR HEART DISEASE BY GEOGRAPHIC REGION

4.1 World Historic Vasodilators for Heart Disease Market Size by Geographic Region (2021-2026)

4.1.1 Global Vasodilators for Heart Disease Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Vasodilators for Heart Disease Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Vasodilators for Heart Disease Market Size by Country/Region (2021-2026)

4.2.1 Global Vasodilators for Heart Disease Annual Sales by Country/Region (2021-2026)

4.2.2 Global Vasodilators for Heart Disease Annual Revenue by Country/Region

(2021-2026)

4.3 Americas Vasodilators for Heart Disease Sales Growth

4.4 APAC Vasodilators for Heart Disease Sales Growth

4.5 Europe Vasodilators for Heart Disease Sales Growth

4.6 Middle East & Africa Vasodilators for Heart Disease Sales Growth

5 AMERICAS

5.1 Americas Vasodilators for Heart Disease Sales by Country

5.1.1 Americas Vasodilators for Heart Disease Sales by Country (2021-2026)

5.1.2 Americas Vasodilators for Heart Disease Revenue by Country (2021-2026)

5.2 Americas Vasodilators for Heart Disease Sales by Type (2021-2026)

5.3 Americas Vasodilators for Heart Disease Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Vasodilators for Heart Disease Sales by Region

6.1.1 APAC Vasodilators for Heart Disease Sales by Region (2021-2026)

6.1.2 APAC Vasodilators for Heart Disease Revenue by Region (2021-2026)

6.2 APAC Vasodilators for Heart Disease Sales by Type (2021-2026)

6.3 APAC Vasodilators for Heart Disease Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Vasodilators for Heart Disease by Country

7.1.1 Europe Vasodilators for Heart Disease Sales by Country (2021-2026)

7.1.2 Europe Vasodilators for Heart Disease Revenue by Country (2021-2026)

7.2 Europe Vasodilators for Heart Disease Sales by Type (2021-2026)

7.3 Europe Vasodilators for Heart Disease Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Vasodilators for Heart Disease by Country

8.1.1 Middle East & Africa Vasodilators for Heart Disease Sales by Country (2021-2026)

8.1.2 Middle East & Africa Vasodilators for Heart Disease Revenue by Country (2021-2026)

8.2 Middle East & Africa Vasodilators for Heart Disease Sales by Type (2021-2026)

8.3 Middle East & Africa Vasodilators for Heart Disease Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Vasodilators for Heart Disease

10.3 Manufacturing Process Analysis of Vasodilators for Heart Disease

10.4 Industry Chain Structure of Vasodilators for Heart Disease

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Vasodilators for Heart Disease Distributors
- 11.3 Vasodilators for Heart Disease Customer

12 WORLD FORECAST REVIEW FOR VASODILATORS FOR HEART DISEASE BY GEOGRAPHIC REGION

- 12.1 Global Vasodilators for Heart Disease Market Size Forecast by Region
 - 12.1.1 Global Vasodilators for Heart Disease Forecast by Region (2027-2032)
 - 12.1.2 Global Vasodilators for Heart Disease Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Vasodilators for Heart Disease Forecast by Type (2027-2032)
- 12.7 Global Vasodilators for Heart Disease Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 Copperhead Chemical Company
 - 13.1.1 Copperhead Chemical Company Company Information
 - 13.1.2 Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolios and Specifications
 - 13.1.3 Copperhead Chemical Company Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 Copperhead Chemical Company Main Business Overview
 - 13.1.5 Copperhead Chemical Company Latest Developments
- 13.2 Pfizer
 - 13.2.1 Pfizer Company Information
 - 13.2.2 Pfizer Vasodilators for Heart Disease Product Portfolios and Specifications
 - 13.2.3 Pfizer Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 Pfizer Main Business Overview
 - 13.2.5 Pfizer Latest Developments
- 13.3 Axplora
 - 13.3.1 Axplora Company Information
 - 13.3.2 Axplora Vasodilators for Heart Disease Product Portfolios and Specifications

13.3.3 Axplora Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Axplora Main Business Overview

13.3.5 Axplora Latest Developments

13.4 TORRENT PHARMA INC.

13.4.1 TORRENT PHARMA INC. Company Information

13.4.2 TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolios and Specifications

13.4.3 TORRENT PHARMA INC. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 TORRENT PHARMA INC. Main Business Overview

13.4.5 TORRENT PHARMA INC. Latest Developments

13.5 Sanofi

13.5.1 Sanofi Company Information

13.5.2 Sanofi Vasodilators for Heart Disease Product Portfolios and Specifications

13.5.3 Sanofi Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Sanofi Main Business Overview

13.5.5 Sanofi Latest Developments

13.6 Aditya Chemicals

13.6.1 Aditya Chemicals Company Information

13.6.2 Aditya Chemicals Vasodilators for Heart Disease Product Portfolios and Specifications

13.6.3 Aditya Chemicals Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Aditya Chemicals Main Business Overview

13.6.5 Aditya Chemicals Latest Developments

13.7 Matins Pharma

13.7.1 Matins Pharma Company Information

13.7.2 Matins Pharma Vasodilators for Heart Disease Product Portfolios and Specifications

13.7.3 Matins Pharma Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Matins Pharma Main Business Overview

13.7.5 Matins Pharma Latest Developments

13.8 Shanxi Kangbao Biological Products Co., Ltd.

13.8.1 Shanxi Kangbao Biological Products Co., Ltd. Company Information

13.8.2 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.8.3 Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Shanxi Kangbao Biological Products Co., Ltd. Main Business Overview

13.8.5 Shanxi Kangbao Biological Products Co., Ltd. Latest Developments

13.9 Henan Runhong Pharmaceutical Co., Ltd.

13.9.1 Henan Runhong Pharmaceutical Co., Ltd. Company Information

13.9.2 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.9.3 Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Henan Runhong Pharmaceutical Co., Ltd. Main Business Overview

13.9.5 Henan Runhong Pharmaceutical Co., Ltd. Latest Developments

13.10 Beijing Yimin Pharmaceutical Co., Ltd.

13.10.1 Beijing Yimin Pharmaceutical Co., Ltd. Company Information

13.10.2 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.10.3 Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Beijing Yimin Pharmaceutical Co., Ltd. Main Business Overview

13.10.5 Beijing Yimin Pharmaceutical Co., Ltd. Latest Developments

13.11 Beijing Hengsheng Pharmaceutical Co., Ltd.

13.11.1 Beijing Hengsheng Pharmaceutical Co., Ltd. Company Information

13.11.2 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.11.3 Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Beijing Hengsheng Pharmaceutical Co., Ltd. Main Business Overview

13.11.5 Beijing Hengsheng Pharmaceutical Co., Ltd. Latest Developments

13.12 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

13.12.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information

13.12.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.12.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Main Business Overview

13.12.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Latest Developments

13.13 Sancai Shiqi Pharmaceutical Co., Ltd.

13.13.1 Sancai Shiqi Pharmaceutical Co., Ltd. Company Information

13.13.2 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product

Portfolios and Specifications

13.13.3 Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 Sancai Shiqi Pharmaceutical Co., Ltd. Main Business Overview

13.13.5 Sancai Shiqi Pharmaceutical Co., Ltd. Latest Developments

13.14 Lunan Beite Pharmaceutical Co., Ltd.

13.14.1 Lunan Beite Pharmaceutical Co., Ltd. Company Information

13.14.2 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.14.3 Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.14.4 Lunan Beite Pharmaceutical Co., Ltd. Main Business Overview

13.14.5 Lunan Beite Pharmaceutical Co., Ltd. Latest Developments

13.15 Shandong Fangming Pharmaceutical Group Co., Ltd.

13.15.1 Shandong Fangming Pharmaceutical Group Co., Ltd. Company Information

13.15.2 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.15.3 Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.15.4 Shandong Fangming Pharmaceutical Group Co., Ltd. Main Business Overview

13.15.5 Shandong Fangming Pharmaceutical Group Co., Ltd. Latest Developments

13.16 Chenxin Pharmaceutical Co., Ltd.

13.16.1 Chenxin Pharmaceutical Co., Ltd. Company Information

13.16.2 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.16.3 Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Chenxin Pharmaceutical Co., Ltd. Main Business Overview

13.16.5 Chenxin Pharmaceutical Co., Ltd. Latest Developments

13.17 Anhui Fengyuan Pharmaceutical Co., Ltd.

13.17.1 Anhui Fengyuan Pharmaceutical Co., Ltd. Company Information

13.17.2 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.17.3 Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Anhui Fengyuan Pharmaceutical Co., Ltd. Main Business Overview

13.17.5 Anhui Fengyuan Pharmaceutical Co., Ltd. Latest Developments

13.18 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd.

13.18.1 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Company

Information

13.18.2 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.18.3 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Main Business Overview

13.18.5 Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Latest Developments

13.19 Shanghai Aifa Pharmaceutical Co., Ltd.

13.19.1 Shanghai Aifa Pharmaceutical Co., Ltd. Company Information

13.19.2 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.19.3 Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.19.4 Shanghai Aifa Pharmaceutical Co., Ltd. Main Business Overview

13.19.5 Shanghai Aifa Pharmaceutical Co., Ltd. Latest Developments

13.20 Shandong New Era Pharmaceutical Co., Ltd.

13.20.1 Shandong New Era Pharmaceutical Co., Ltd. Company Information

13.20.2 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.20.3 Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.20.4 Shandong New Era Pharmaceutical Co., Ltd. Main Business Overview

13.20.5 Shandong New Era Pharmaceutical Co., Ltd. Latest Developments

13.21 Shanghai Hefeng Pharmaceutical Co., Ltd.

13.21.1 Shanghai Hefeng Pharmaceutical Co., Ltd. Company Information

13.21.2 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.21.3 Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.21.4 Shanghai Hefeng Pharmaceutical Co., Ltd. Main Business Overview

13.21.5 Shanghai Hefeng Pharmaceutical Co., Ltd. Latest Developments

13.22 Jiangsu Shenlong Pharmaceutical Co., Ltd.

13.22.1 Jiangsu Shenlong Pharmaceutical Co., Ltd. Company Information

13.22.2 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.22.3 Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.22.4 Jiangsu Shenlong Pharmaceutical Co., Ltd. Main Business Overview
- 13.22.5 Jiangsu Shenlong Pharmaceutical Co., Ltd. Latest Developments
- 13.23 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd.
 - 13.23.1 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Company Information
 - 13.23.2 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
 - 13.23.3 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.23.4 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Main Business Overview
 - 13.23.5 Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Latest Developments
- 13.24 Hulunbeier Songlu Pharmaceutical Co., Ltd.
 - 13.24.1 Hulunbeier Songlu Pharmaceutical Co., Ltd. Company Information
 - 13.24.2 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
 - 13.24.3 Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.24.4 Hulunbeier Songlu Pharmaceutical Co., Ltd. Main Business Overview
 - 13.24.5 Hulunbeier Songlu Pharmaceutical Co., Ltd. Latest Developments
- 13.25 Chongqing Yaoyou Pharmaceutical Co., Ltd.
 - 13.25.1 Chongqing Yaoyou Pharmaceutical Co., Ltd. Company Information
 - 13.25.2 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
 - 13.25.3 Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.25.4 Chongqing Yaoyou Pharmaceutical Co., Ltd. Main Business Overview
 - 13.25.5 Chongqing Yaoyou Pharmaceutical Co., Ltd. Latest Developments
- 13.26 Jiangsu Jiuxu Pharmaceutical Co., Ltd.
 - 13.26.1 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Company Information
 - 13.26.2 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
 - 13.26.3 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.26.4 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Main Business Overview
 - 13.26.5 Jiangsu Jiuxu Pharmaceutical Co., Ltd. Latest Developments
- 13.27 Jiangxi Haiersi Pharmaceutical Co., Ltd.
 - 13.27.1 Jiangxi Haiersi Pharmaceutical Co., Ltd. Company Information

13.27.2 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.27.3 Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.27.4 Jiangxi Haiersi Pharmaceutical Co., Ltd. Main Business Overview

13.27.5 Jiangxi Haiersi Pharmaceutical Co., Ltd. Latest Developments

13.28 Southwest Pharmaceutical Co., Ltd.

13.28.1 Southwest Pharmaceutical Co., Ltd. Company Information

13.28.2 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

13.28.3 Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales, Revenue, Price and Gross Margin (2021-2026)

13.28.4 Southwest Pharmaceutical Co., Ltd. Main Business Overview

13.28.5 Southwest Pharmaceutical Co., Ltd. Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Vasodilators for Heart Disease Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Vasodilators for Heart Disease Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Nitroglycerin

Table 4. Major Players of Isosorbide Dinitrate

Table 5. Major Players of Isosorbide Mononitrate

Table 6. Major Players of Nicorandil

Table 7. Global Vasodilators for Heart Disease Sales by Type (2021-2026) & (K Units)

Table 8. Global Vasodilators for Heart Disease Sales Market Share by Type (2021-2026)

Table 9. Global Vasodilators for Heart Disease Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Vasodilators for Heart Disease Revenue Market Share by Type (2021-2026)

Table 11. Global Vasodilators for Heart Disease Sale Price by Type (2021-2026) & (US\$/Unit)

Table 12. Global Vasodilators for Heart Disease Sale by Application (2021-2026) & (K Units)

Table 13. Global Vasodilators for Heart Disease Sale Market Share by Application (2021-2026)

Table 14. Global Vasodilators for Heart Disease Revenue by Application (2021-2026) & (\$ million)

Table 15. Global Vasodilators for Heart Disease Revenue Market Share by Application (2021-2026)

Table 16. Global Vasodilators for Heart Disease Sale Price by Application (2021-2026) & (US\$/Unit)

Table 17. Global Vasodilators for Heart Disease Sales by Company (2021-2026) & (K Units)

Table 18. Global Vasodilators for Heart Disease Sales Market Share by Company (2021-2026)

Table 19. Global Vasodilators for Heart Disease Revenue by Company (2021-2026) & (\$ millions)

Table 20. Global Vasodilators for Heart Disease Revenue Market Share by Company (2021-2026)

Table 21. Global Vasodilators for Heart Disease Sale Price by Company (2021-2026) & (US\$/Unit)

Table 22. Key Manufacturers Vasodilators for Heart Disease Producing Area Distribution and Sales Area

Table 23. Players Vasodilators for Heart Disease Products Offered

Table 24. Vasodilators for Heart Disease Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Vasodilators for Heart Disease Sales by Geographic Region (2021-2026) & (K Units)

Table 28. Global Vasodilators for Heart Disease Sales Market Share Geographic Region (2021-2026)

Table 29. Global Vasodilators for Heart Disease Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 30. Global Vasodilators for Heart Disease Revenue Market Share by Geographic Region (2021-2026)

Table 31. Global Vasodilators for Heart Disease Sales by Country/Region (2021-2026) & (K Units)

Table 32. Global Vasodilators for Heart Disease Sales Market Share by Country/Region (2021-2026)

Table 33. Global Vasodilators for Heart Disease Revenue by Country/Region (2021-2026) & (\$ millions)

Table 34. Global Vasodilators for Heart Disease Revenue Market Share by Country/Region (2021-2026)

Table 35. Americas Vasodilators for Heart Disease Sales by Country (2021-2026) & (K Units)

Table 36. Americas Vasodilators for Heart Disease Sales Market Share by Country (2021-2026)

Table 37. Americas Vasodilators for Heart Disease Revenue by Country (2021-2026) & (\$ millions)

Table 38. Americas Vasodilators for Heart Disease Sales by Type (2021-2026) & (K Units)

Table 39. Americas Vasodilators for Heart Disease Sales by Application (2021-2026) & (K Units)

Table 40. APAC Vasodilators for Heart Disease Sales by Region (2021-2026) & (K Units)

Table 41. APAC Vasodilators for Heart Disease Sales Market Share by Region (2021-2026)

- Table 42. APAC Vasodilators for Heart Disease Revenue by Region (2021-2026) & (\$ millions)
- Table 43. APAC Vasodilators for Heart Disease Sales by Type (2021-2026) & (K Units)
- Table 44. APAC Vasodilators for Heart Disease Sales by Application (2021-2026) & (K Units)
- Table 45. Europe Vasodilators for Heart Disease Sales by Country (2021-2026) & (K Units)
- Table 46. Europe Vasodilators for Heart Disease Revenue by Country (2021-2026) & (\$ millions)
- Table 47. Europe Vasodilators for Heart Disease Sales by Type (2021-2026) & (K Units)
- Table 48. Europe Vasodilators for Heart Disease Sales by Application (2021-2026) & (K Units)
- Table 49. Middle East & Africa Vasodilators for Heart Disease Sales by Country (2021-2026) & (K Units)
- Table 50. Middle East & Africa Vasodilators for Heart Disease Revenue Market Share by Country (2021-2026)
- Table 51. Middle East & Africa Vasodilators for Heart Disease Sales by Type (2021-2026) & (K Units)
- Table 52. Middle East & Africa Vasodilators for Heart Disease Sales by Application (2021-2026) & (K Units)
- Table 53. Key Market Drivers & Growth Opportunities of Vasodilators for Heart Disease
- Table 54. Key Market Challenges & Risks of Vasodilators for Heart Disease
- Table 55. Key Industry Trends of Vasodilators for Heart Disease
- Table 56. Vasodilators for Heart Disease Raw Material
- Table 57. Key Suppliers of Raw Materials
- Table 58. Vasodilators for Heart Disease Distributors List
- Table 59. Vasodilators for Heart Disease Customer List
- Table 60. Global Vasodilators for Heart Disease Sales Forecast by Region (2027-2032) & (K Units)
- Table 61. Global Vasodilators for Heart Disease Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 62. Americas Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (K Units)
- Table 63. Americas Vasodilators for Heart Disease Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 64. APAC Vasodilators for Heart Disease Sales Forecast by Region (2027-2032) & (K Units)
- Table 65. APAC Vasodilators for Heart Disease Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

- Table 66. Europe Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (K Units)
- Table 67. Europe Vasodilators for Heart Disease Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 68. Middle East & Africa Vasodilators for Heart Disease Sales Forecast by Country (2027-2032) & (K Units)
- Table 69. Middle East & Africa Vasodilators for Heart Disease Revenue Forecast by Country (2027-2032) & (\$ millions)
- Table 70. Global Vasodilators for Heart Disease Sales Forecast by Type (2027-2032) & (K Units)
- Table 71. Global Vasodilators for Heart Disease Revenue Forecast by Type (2027-2032) & (\$ millions)
- Table 72. Global Vasodilators for Heart Disease Sales Forecast by Application (2027-2032) & (K Units)
- Table 73. Global Vasodilators for Heart Disease Revenue Forecast by Application (2027-2032) & (\$ millions)
- Table 74. Copperhead Chemical Company Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 75. Copperhead Chemical Company Vasodilators for Heart Disease Product Portfolios and Specifications
- Table 76. Copperhead Chemical Company Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 77. Copperhead Chemical Company Main Business
- Table 78. Copperhead Chemical Company Latest Developments
- Table 79. Pfizer Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 80. Pfizer Vasodilators for Heart Disease Product Portfolios and Specifications
- Table 81. Pfizer Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 82. Pfizer Main Business
- Table 83. Pfizer Latest Developments
- Table 84. Axplora Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 85. Axplora Vasodilators for Heart Disease Product Portfolios and Specifications
- Table 86. Axplora Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 87. Axplora Main Business
- Table 88. Axplora Latest Developments
- Table 89. TORRENT PHARMA INC. Basic Information, Vasodilators for Heart Disease

Manufacturing Base, Sales Area and Its Competitors

Table 90. TORRENT PHARMA INC. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 91. TORRENT PHARMA INC. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 92. TORRENT PHARMA INC. Main Business

Table 93. TORRENT PHARMA INC. Latest Developments

Table 94. Sanofi Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 95. Sanofi Vasodilators for Heart Disease Product Portfolios and Specifications

Table 96. Sanofi Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 97. Sanofi Main Business

Table 98. Sanofi Latest Developments

Table 99. Aditya Chemicals Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 100. Aditya Chemicals Vasodilators for Heart Disease Product Portfolios and Specifications

Table 101. Aditya Chemicals Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 102. Aditya Chemicals Main Business

Table 103. Aditya Chemicals Latest Developments

Table 104. Matins Pharma Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 105. Matins Pharma Vasodilators for Heart Disease Product Portfolios and Specifications

Table 106. Matins Pharma Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 107. Matins Pharma Main Business

Table 108. Matins Pharma Latest Developments

Table 109. Shanxi Kangbao Biological Products Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 110. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 111. Shanxi Kangbao Biological Products Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 112. Shanxi Kangbao Biological Products Co., Ltd. Main Business

Table 113. Shanxi Kangbao Biological Products Co., Ltd. Latest Developments

Table 114. Henan Runhong Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 115. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 116. Henan Runhong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 117. Henan Runhong Pharmaceutical Co., Ltd. Main Business

Table 118. Henan Runhong Pharmaceutical Co., Ltd. Latest Developments

Table 119. Beijing Yimin Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 120. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 121. Beijing Yimin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 122. Beijing Yimin Pharmaceutical Co., Ltd. Main Business

Table 123. Beijing Yimin Pharmaceutical Co., Ltd. Latest Developments

Table 124. Beijing Hengsheng Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 125. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 126. Beijing Hengsheng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 127. Beijing Hengsheng Pharmaceutical Co., Ltd. Main Business

Table 128. Beijing Hengsheng Pharmaceutical Co., Ltd. Latest Developments

Table 129. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 130. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 131. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 132. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Main Business

Table 133. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Latest Developments

Table 134. Sancai Shiqi Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 135. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 136. Sancai Shiqi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 137. Sancai Shiqi Pharmaceutical Co., Ltd. Main Business

- Table 138. Sancai Shiqi Pharmaceutical Co., Ltd. Latest Developments
- Table 139. Lunan Beite Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 140. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
- Table 141. Lunan Beite Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 142. Lunan Beite Pharmaceutical Co., Ltd. Main Business
- Table 143. Lunan Beite Pharmaceutical Co., Ltd. Latest Developments
- Table 144. Shandong Fangming Pharmaceutical Group Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 145. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
- Table 146. Shandong Fangming Pharmaceutical Group Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 147. Shandong Fangming Pharmaceutical Group Co., Ltd. Main Business
- Table 148. Shandong Fangming Pharmaceutical Group Co., Ltd. Latest Developments
- Table 149. Chenxin Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 150. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
- Table 151. Chenxin Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 152. Chenxin Pharmaceutical Co., Ltd. Main Business
- Table 153. Chenxin Pharmaceutical Co., Ltd. Latest Developments
- Table 154. Anhui Fengyuan Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 155. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications
- Table 156. Anhui Fengyuan Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 157. Anhui Fengyuan Pharmaceutical Co., Ltd. Main Business
- Table 158. Anhui Fengyuan Pharmaceutical Co., Ltd. Latest Developments
- Table 159. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors
- Table 160. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 161. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 162. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Main Business

Table 163. Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd. Latest Developments

Table 164. Shanghai Aifa Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 165. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 166. Shanghai Aifa Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 167. Shanghai Aifa Pharmaceutical Co., Ltd. Main Business

Table 168. Shanghai Aifa Pharmaceutical Co., Ltd. Latest Developments

Table 169. Shandong New Era Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 170. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 171. Shandong New Era Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 172. Shandong New Era Pharmaceutical Co., Ltd. Main Business

Table 173. Shandong New Era Pharmaceutical Co., Ltd. Latest Developments

Table 174. Shanghai Hefeng Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 175. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 176. Shanghai Hefeng Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 177. Shanghai Hefeng Pharmaceutical Co., Ltd. Main Business

Table 178. Shanghai Hefeng Pharmaceutical Co., Ltd. Latest Developments

Table 179. Jiangsu Shenlong Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 180. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 181. Jiangsu Shenlong Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 182. Jiangsu Shenlong Pharmaceutical Co., Ltd. Main Business

Table 183. Jiangsu Shenlong Pharmaceutical Co., Ltd. Latest Developments

Table 184. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Basic

Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 185. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 186. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 187. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Main Business

Table 188. Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. Latest Developments

Table 189. Hulunbeier Songlu Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 190. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 191. Hulunbeier Songlu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 192. Hulunbeier Songlu Pharmaceutical Co., Ltd. Main Business

Table 193. Hulunbeier Songlu Pharmaceutical Co., Ltd. Latest Developments

Table 194. Chongqing Yaoyou Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 195. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 196. Chongqing Yaoyou Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 197. Chongqing Yaoyou Pharmaceutical Co., Ltd. Main Business

Table 198. Chongqing Yaoyou Pharmaceutical Co., Ltd. Latest Developments

Table 199. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 200. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 201. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 202. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Main Business

Table 203. Jiangsu Jiuxu Pharmaceutical Co., Ltd. Latest Developments

Table 204. Jiangxi Haiersi Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 205. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 206. Jiangxi Haiersi Pharmaceutical Co., Ltd. Vasodilators for Heart Disease

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 207. Jiangxi Haiersi Pharmaceutical Co., Ltd. Main Business

Table 208. Jiangxi Haiersi Pharmaceutical Co., Ltd. Latest Developments

Table 209. Southwest Pharmaceutical Co., Ltd. Basic Information, Vasodilators for Heart Disease Manufacturing Base, Sales Area and Its Competitors

Table 210. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Product Portfolios and Specifications

Table 211. Southwest Pharmaceutical Co., Ltd. Vasodilators for Heart Disease Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 212. Southwest Pharmaceutical Co., Ltd. Main Business

Table 213. Southwest Pharmaceutical Co., Ltd. Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Vasodilators for Heart Disease
- Figure 2. Vasodilators for Heart Disease Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Vasodilators for Heart Disease Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Vasodilators for Heart Disease Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Vasodilators for Heart Disease Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Vasodilators for Heart Disease Sales Market Share by Country/Region (2025)
- Figure 10. Vasodilators for Heart Disease Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Nitroglycerin
- Figure 12. Product Picture of Isosorbide Dinitrate
- Figure 13. Product Picture of Isosorbide Mononitrate
- Figure 14. Product Picture of Nicorandil
- Figure 15. Global Vasodilators for Heart Disease Sales Market Share by Type in 2026
- Figure 16. Global Vasodilators for Heart Disease Revenue Market Share by Type (2021-2026)
- Figure 17. Vasodilators for Heart Disease Consumed in Hospital
- Figure 18. Global Vasodilators for Heart Disease Market: Hospital (2021-2026) & (K Units)
- Figure 19. Vasodilators for Heart Disease Consumed in Clinic
- Figure 20. Global Vasodilators for Heart Disease Market: Clinic (2021-2026) & (K Units)
- Figure 21. Vasodilators for Heart Disease Consumed in Other
- Figure 22. Global Vasodilators for Heart Disease Market: Other (2021-2026) & (K Units)
- Figure 23. Global Vasodilators for Heart Disease Sale Market Share by Application (2025)
- Figure 24. Global Vasodilators for Heart Disease Revenue Market Share by Application in 2026
- Figure 25. Vasodilators for Heart Disease Sales by Company in 2026 (K Units)
- Figure 26. Global Vasodilators for Heart Disease Sales Market Share by Company in 2026
- Figure 27. Vasodilators for Heart Disease Revenue by Company in 2026 (\$ millions)

Figure 28. Global Vasodilators for Heart Disease Revenue Market Share by Company in 2026

Figure 29. Global Vasodilators for Heart Disease Sales Market Share by Geographic Region (2021-2026)

Figure 30. Global Vasodilators for Heart Disease Revenue Market Share by Geographic Region in 2026

Figure 31. Americas Vasodilators for Heart Disease Sales 2021-2026 (K Units)

Figure 32. Americas Vasodilators for Heart Disease Revenue 2021-2026 (\$ millions)

Figure 33. APAC Vasodilators for Heart Disease Sales 2021-2026 (K Units)

Figure 34. APAC Vasodilators for Heart Disease Revenue 2021-2026 (\$ millions)

Figure 35. Europe Vasodilators for Heart Disease Sales 2021-2026 (K Units)

Figure 36. Europe Vasodilators for Heart Disease Revenue 2021-2026 (\$ millions)

Figure 37. Middle East & Africa Vasodilators for Heart Disease Sales 2021-2026 (K Units)

Figure 38. Middle East & Africa Vasodilators for Heart Disease Revenue 2021-2026 (\$ millions)

Figure 39. Americas Vasodilators for Heart Disease Sales Market Share by Country in 2026

Figure 40. Americas Vasodilators for Heart Disease Revenue Market Share by Country (2021-2026)

Figure 41. Americas Vasodilators for Heart Disease Sales Market Share by Type (2021-2026)

Figure 42. Americas Vasodilators for Heart Disease Sales Market Share by Application (2021-2026)

Figure 43. United States Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 44. Canada Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 45. Mexico Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 46. Brazil Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 47. APAC Vasodilators for Heart Disease Sales Market Share by Region in 2026

Figure 48. APAC Vasodilators for Heart Disease Revenue Market Share by Region (2021-2026)

Figure 49. APAC Vasodilators for Heart Disease Sales Market Share by Type (2021-2026)

Figure 50. APAC Vasodilators for Heart Disease Sales Market Share by Application (2021-2026)

Figure 51. China Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 52. Japan Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 53. South Korea Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 54. Southeast Asia Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 55. India Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 56. Australia Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 57. China Taiwan Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 58. Europe Vasodilators for Heart Disease Sales Market Share by Country in 2026

Figure 59. Europe Vasodilators for Heart Disease Revenue Market Share by Country (2021-2026)

Figure 60. Europe Vasodilators for Heart Disease Sales Market Share by Type (2021-2026)

Figure 61. Europe Vasodilators for Heart Disease Sales Market Share by Application (2021-2026)

Figure 62. Germany Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 63. France Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 64. UK Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 65. Italy Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 66. Russia Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 67. Middle East & Africa Vasodilators for Heart Disease Sales Market Share by Country (2021-2026)

Figure 68. Middle East & Africa Vasodilators for Heart Disease Sales Market Share by Type (2021-2026)

Figure 69. Middle East & Africa Vasodilators for Heart Disease Sales Market Share by Application (2021-2026)

Figure 70. Egypt Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 71. South Africa Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 72. Israel Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 73. Turkey Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 74. GCC Countries Vasodilators for Heart Disease Revenue Growth 2021-2026 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Vasodilators for Heart Disease in 2026

Figure 76. Manufacturing Process Analysis of Vasodilators for Heart Disease

Figure 77. Industry Chain Structure of Vasodilators for Heart Disease

Figure 78. Channels of Distribution

Figure 79. Global Vasodilators for Heart Disease Sales Market Forecast by Region (2027-2032)

Figure 80. Global Vasodilators for Heart Disease Revenue Market Share Forecast by Region (2027-2032)

Figure 81. Global Vasodilators for Heart Disease Sales Market Share Forecast by Type (2027-2032)

Figure 82. Global Vasodilators for Heart Disease Revenue Market Share Forecast by Type (2027-2032)

Figure 83. Global Vasodilators for Heart Disease Sales Market Share Forecast by Application (2027-2032)

Figure 84. Global Vasodilators for Heart Disease Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Vasodilators for Heart Disease Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G5705A1A14E9EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5705A1A14E9EN.html>